Prostate cancer treatment of COVID-19
-a randomized clinical trial
COVIDENZA is a multi-centre randomized clinical trial investigating if enzalutamide may be beneficial in COVID-19. Men have higher risk of severe symptoms of COVID-19, the reason is unknown, but may be due to the androgens, male sex steroids. Studies, both epidemiological and experimental, support our hypothesis that the antiandrogen drug Enzalutamide may limit the severity of Covid-19 symptoms.
The trial has approval from both the Swedish ethical review board and the Swedish Medical Product Agency.
Trial synopsis
Sponsor
Region Västerbotten (PI Andreas Josefsson)
Principal Investigators
PI Andreas Josefsson (for more information on Umu-link or WCMM-link )
Co-PI Karin Welen (for more information follow the link)
Trial sites
Umeå, Göteborg, Malmö, Jönköping, Sundsvall and Linköping
More sites are pending
Financing
Astellas Pharma Europe Ltd. (Unconditional grants; no part of initiation, protocol, management or analysis of the trial)
Wallenberg Center for Molecular Medicine (see also link)
For the trial sites
For the investigators, documentation is available at the following link:
Contact information
If you have any questions please contact us by e-mail Covidenza@umu.se